Harvard Apparatus Regenerative Technology (HART -1.1%) hires Saverio La Francesca, M.D. as Chief Medical Officer.
Dr. Francesca joins the firm from the DeBakey Heart and Vascular Center in Houston. Prior to that he was an attending surgeon at the Department of Cardiopulmonary Transplantation at the Texas Heart Institute. He has direct experience in more than 1,000 organ transplants including 200+ heart and lung transplant procedures.
HART's lead product is a bioreactor/synthetic scaffold system for trachea transplants. Limited Phase 1 clinical trials have begun in Sweden and Russia.